Skip to main content

Table 5 Treatment of anemic IBD patients (N = 687)

From: The burden and management of anemia in Greek patients with inflammatory bowel disease: a retrospective, multicenter, observational study

 

Anemia total (N = 687)

Episodic anemia Group B (N = 413)

Recurrent/Persistent anemia

Group C (N = 274)

P

Anemia treatment (%)

535 (77.9)

300 (72.6)

235 (85.8)

 < 0.0001

CD/UC (%)

327/208 (61.2/38.8)

167/133 (55.7/44.3)

160/75 (68.1/31.9)

 

Iron Administration (%)

485 (90.6)

286 (95. 3)

213 (90.6)

 

Iron PO/IVa (%)

142/392 (29.3/ 81)

72/214 (25.2/75)

70/178 (32.9/83.6)

 

B12 Administration (%)

113 (21.1)

48 (16)

65 (27.6)

0.0014

Folic acid Administrationb (%)

182 (33.9)

80 (26.7)

102 (43.4)

 < 0.0001

Blood Transfusion (%)

68 (12.7)

36 (12)

32 (13.6)

0.0061

  1. Group A never anemic patients, Group B episodically anemic patients, Group C recurrently/persistently anemic patients
  2. UC, Ulcerative Colitis; CD, Crohn’s Disease; PO, Per Os; IV, Intravenously
  3. aPatients who were initially treated with oral iron, were subsequently treated with intravenous iron due to either lack of response or adverse events that led to discontinuation of the oral formulation
  4. bApart from concurrent administration with MTX
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us